Advertisement

Effects of atorvastatin on serum soluble receptors for advanced glycation end-products in type 2 diabetes

      Abstract

      Objective

      The receptor for advanced glycation end-products (RAGE) plays an important role in the pathogenesis of diabetic complications and atherosclerosis. Interfering with the activation of RAGE by using a soluble form of the receptor (sRAGE) ameliorates the vascular complications of diabetes in animal models. We have investigated whether statin can influence the expression of sRAGE and esRAGE (a splice variant of sRAGE) in vitro and in vivo.

      Methods

      THP-1 cells were incubated with atorvastatin in vitro and sRAGE and esRAGE in the medium was measured by Western immunoblot. Serum levels of sRAGE and esRAGE were measured by ELISA in archived serum samples from a previous randomized double-blind placebo-controlled clinical trial that explored the cardiovascular effects of atorvastatin in hypercholesterolemic Chinese type 2 diabetic patients.

      Results

      sRAGE and esRAGE were induced by atorvastatin in a time- and dose-dependent manner in THP-1 cells. In the diabetic patients, there was a significant increase in serum sRAGE (p < 0.05) and esRAGE (p < 0.01) in the atorvastatin group at 6-month, but no change in placebo group. Serum esRAGE was higher in atorvastatin group than placebo group [median 240.5 pg/ml (interquartile range 186.5–377.3) vs 194.8 pg/ml (124.1–347.9) respectively, p < 0.01] at 6-month, whereas the differences in sRAGE did not reach statistical significance (p = 0.051). There was a correlation between the increase of serum esRAGE and reduction of serum LDL (r = −0.36, p = 0.001).

      Conclusions

      Statins are known to have pleiotropic effects and we have shown that atorvastatin can increase circulating esRAGE levels in type 2 diabetic patients.

      Keywords

      To read this article in full you will need to make a payment

      Purchase one-time access:

      Academic & Personal: 24 hour online accessCorporate R&D Professionals: 24 hour online access
      One-time access price info
      • For academic or personal research use, select 'Academic and Personal'
      • For corporate R&D use, select 'Corporate R&D Professionals'

      Subscribe:

      Subscribe to Atherosclerosis
      Already a print subscriber? Claim online access
      Already an online subscriber? Sign in
      Institutional Access: Sign in to ScienceDirect

      References

        • Bucciarelli L.G.
        • Wendt T.
        • Rong L.
        • et al.
        RAGE is a multiligand receptor of the immunoglobulin superfamily: implications for homeostasis and chronic disease.
        Cell Mol Life Sci. 2002; 59: 1117-1128
        • Schmidt A.M.
        • Yan S.D.
        • Wautier J.L.
        • Stern D.
        Activation of receptor for advanced glycation end products: a mechanism for chronic vascular dysfunction in diabetic vasculopathy and atherosclerosis.
        Circ Res. 1999; 84: 489-497
        • Yamamoto Y.
        • Yamagishi S.
        • Yonekura H.
        • et al.
        Roles of the AGE-RAGE system in vascular injury in diabetes.
        Ann N Y Acad Sci. 2000; 902: 163-170
        • Wautier J.L.
        • Zoukourian C.
        • Chappey O.
        • et al.
        Receptor-mediated endothelial cell dysfunction in diabetic vasculopathy. Soluble receptor for advanced glycation end products blocks hyperpermeability in diabetic rats.
        J Clin Invest. 1996; 97: 238-243
        • Park L.
        • Raman K.G.
        • Lee K.J.
        • et al.
        Suppression of accelerated diabetic atherosclerosis by the soluble receptor for advanced glycation endproducts.
        Nat Med. 1998; 4: 1025-1031
        • Goova M.T.
        • Li J.
        • Kislinger T.
        • et al.
        Blockade of receptor for advanced glycation end-products restores effective wound healing in diabetic mice.
        Am J Pathol. 2001; 159: 513-525
        • Bucciarelli L.G.
        • Wendt T.
        • Qu W.
        • et al.
        RAGE blockade stabilizes established atherosclerosis in diabetic apolipoprotein E-null mice.
        Circulation. 2002; 106: 2827-2835
        • Geroldi D.
        • Falcone C.
        • Emanuele E.
        Soluble receptor for advanced glycation end products: from disease marker to potential therapeutic target.
        Curr Med Chem. 2006; 13: 1971-1978
        • Basta G.
        Receptor for advanced glycation endproducts and atherosclerosis: From basic mechanisms to clinical implications.
        Atherosclerosis. 2008; 196: 9-21
        • Ramasamy R.
        • Yan S.F.
        • Schmidt A.M.
        RAGE: therapeutic target and biomarker of the inflammatory response-the evidence mounts.
        J Leukoc Biol. 2009; 86: 505-512
        • Yonekura H.
        • Yamamoto Y.
        • Sakurai S.
        • et al.
        Novel splice variants of the receptor for advanced glycation end-products expressed in human vascular endothelial cells and pericytes, and their putative roles in diabetes-induced vascular injury.
        Biochem J. 2003; 370: 1097-1109
        • Schlueter C.
        • Hauke S.
        • Flohr A.M.
        • Rogalla P.
        • Bullerdiek J.
        Tissue-specific expression patterns of the RAGE receptor and its soluble forms–a result of regulated alternative splicing?.
        Biochim Biophys Acta. 2003; 1630: 1-6
        • Park I.H.
        • Yeon S.I.
        • Youn J.H.
        • et al.
        Expression of a novel secreted splice variant of the receptor for advanced glycation end products (RAGE) in human brain astrocytes and peripheral blood mononuclear cells.
        Mol Immunol. 2004; 40: 1203-1211
        • Hanford L.E.
        • Enghild J.J.
        • Valnickova Z.
        • et al.
        Purification and characterization of mouse soluble receptor for advanced glycation end products (sRAGE).
        J Biol Chem. 2004; 279: 50019-50024
        • Cheng C.
        • Tsuneyama K.
        • Kominami R.
        • et al.
        Expression profiling of endogenous secretory receptor for advanced glycation end products in human organs.
        Mod Pathol. 2005; 18: 1385-1396
      1. Lanati N, Emanuele E, Brondino N, Geroldi D. Soluble RAGE-modulating drugs: state-of-the-art and future perspectives for targeting vascular inflammation. Curr Vasc Pharmacol 2010 [Epub ahead of print].

        • Forbes J.M.
        • Thorpe S.R.
        • Thallas-Bonke V.
        • et al.
        Modulation of soluble receptor for advanced glycation end products by angiotensin-converting enzyme-1 inhibition in diabetic nephropathy.
        J Am Soc Nephrol. 2005; 16: 2363-2372
        • Tan K.C.
        • Chow W.S.
        • Tso A.W.
        • et al.
        Thiazolidinedione increases serum soluble receptor for advanced glycation end products in type 2 diabetes.
        Diabetologia. 2007; 50: 1819-1825
        • Santilli F.
        • Bucciarelli L.
        • Noto D.
        • et al.
        Decreased plasma soluble RAGE in patients with hypercholesterolemia: effects of statins.
        Free Radic Biol Med. 2007; 43: 1255-1262
        • Tan K.C.B.
        • Chow W.S.
        • Tam S.C.
        • Ai V.H.
        • Lam C.H.
        • Lam K.S.
        Atorvastatin lowers C-reactive protein and improves endothelium-dependent vasodilation in type 2 diabetes mellitus.
        J Clin Endocrinol Metab. 2002; 87: 563-568
        • Raucci A.
        • Cugusi S.
        • Antonelli A.
        • et al.
        A soluble form of the receptor for advanced glycation endproducts (RAGE) is produced by proteolytic cleavage of the membrane-bound form by the sheddase a disintegrin and metalloprotease 10 (ADAM10).
        FASEB J. 2008; 22: 3716-3727
        • Hudson B.I.
        • Carter A.M.
        • Harja E.
        • et al.
        Identification, classification, and expression of RAGE gene splice variants.
        FASEB J. 2008; 22: 1572-1580
        • Galichet A.
        • Weibel M.
        • Heizmann C.W.
        Calcium-regulated intramembrane proteolysis of the RAGE receptor.
        Biochem Biophys Res Commun. 2008; 370: 1-5
        • Devangelio E.
        • Santilli F.
        • Formoso G.
        • et al.
        Soluble RAGE in type 2 diabetes: association with oxidative stress.
        Free Radic Biol Med. 2007; 43: 511-518
        • Nakamura K.
        • Yamagishi S.
        • Adachi H.
        • et al.
        Serum levels of sRAGE, the soluble form of receptor for advanced glycation end products, are associated with inflammatory markers in patients with type 2 diabetes.
        Mol Med. 2007; 13: 185-189
        • Jialal I.
        • Stein D.
        • Balis D.
        • Grundy S.M.
        • Adams-Huet B.
        • Devaraj S.
        Effect of hydroxymethyl glutaryl coenzyme a reductase inhibitor therapy on high sensitive C-reactive protein levels.
        Circulation. 2001; 103: 1933-1935
        • Jinnouchi Y.
        • Yamagishi S.
        • Takeuchi M.
        • Ishida S.
        • Jinnouchi J.
        • Jinnouchi T.
        Atorvastatin decreases serum levels of advanced glycation end products (AGEs) in patients with type 2 diabetes.
        Clin Exp Med. 2006; 6: 191-193
        • Tan K.C.
        • Shiu S.W.
        • Chow W.S.
        • Leng L.
        • Bucala R.
        • Betteridge D.J.
        Association between serum level of soluble receptor for advanced glycation end products and circulating advanced glycation end products in type 2 diabetes.
        Diabetologia. 2006; 49: 2756-2762
        • Kalea A.Z.
        • Schmidt A.M.
        • Hudson B.I.
        RAGE: a novel biological and genetic marker for vascular disease.
        Clin Sci (Lond). 2009; 116: 621-637
        • Santilli F.
        • Vazzana N.
        • Bucciarelli L.G.
        • Davi G.
        Soluble forms of RAGE in human diseases: clinical and therapeutical implications.
        Curr Med Chem. 2009; 16: 940-952